LY-404187 (Redirected from LY-404,187)

LY-404187
Clinical data
Other namesLY-404,187; N-2-[4-(4-cyanophenyl)phenyl]propyl-2-propanesulfonamide
ATC code
  • none
Legal status
Legal status
Identifiers
  • N-[2-(4'-cyanobiphenyl-4-yl)propyl]propane-2-sulfonamide
CAS Number
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H22N2O2S
Molar mass342.46 g·mol−1
3D model (JSmol)
  • N#Cc2ccc(cc2)-c1ccc(C(C)CNS(=O)(=O)C(C)C)cc1
  • InChI=1S/C19H28N2O2S/c1-14(2)24(22,23)21-13-15(3)17-8-10-19(11-9-17)18-6-4-16(12-20)5-7-18/h4-7,14-15,17,19,21H,8-11,13H2,1-3H3 ☒N
  • Key:AIALBPYHYGYYRB-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

LY-404187 is an AMPA receptor positive allosteric modulator which was developed by Eli Lilly and Company. It is a member of the biarylpropylsulfonamide class of AMPA receptor potentiators.

LY-404187 has been demonstrated to enhance cognitive function in animal studies, and has also shown effects suggesting antidepressant action as well as having possible application in the treatment of schizophrenia, Parkinson's disease and ADHD. These effects appear to be mediated through multiple mechanisms of action secondary to AMPA receptor potentiation, with a prominent effect seen in research being increased levels of BDNF in the brain. It may therefore be continued on to human trials, although Eli Lilly has developed a whole family of biarylpropylsulfonamide derivatives and it is unclear at this stage which compound is most likely to be selected for further development.

See also



This page was last updated at 2023-11-03 08:27 UTC. Update now. View original page.

All our content comes from Wikipedia and under the Creative Commons Attribution-ShareAlike License.


Top

If mathematical, chemical, physical and other formulas are not displayed correctly on this page, please useFirefox or Safari